Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.

While cancer immunotherapy can produce dramatic responses, only a minority of patients respond to treatment. Reliable response biomarkers are needed to identify responders, and conventional imaging modalities have not proved adequate. Here, we provide a preclinical proof of concept for the use of granzyme B, a downstream effector of tumoral cytotoxic T cells, as an early biomarker for tumors responding to immunotherapy. We designed novel PET imaging probes for the murine and human granzyme B isoforms that specifically and quantitatively bind granzyme B. Immunotherapy-treated mice were imaged prior to therapy-induced tumor volume reduction. Imaging distinguished treated responders from nonresponders with excellent predictive ability. To assess the clinical value of a granzyme B imaging paradigm, biopsy specimens from melanoma patients on checkpoint inhibitor therapy were analyzed. A marked differential in granzyme B expression was observed between treated responders and nonresponders. Additionally, our human probe was able to specifically detect granzyme B expression in human samples, providing a clear candidate for clinical application. Overall, our results suggest granzyme B PET imaging can serve as a quantitatively useful predictive biomarker for efficacious responses to cancer immunotherapy. Cancer Res; 77(9); 2318-27. ©2017 AACR.

[1]  U. Mahmood,et al.  Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy , 2016, The Journal of Nuclear Medicine.

[2]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[3]  I. Weissman,et al.  Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging , 2015, Proceedings of the National Academy of Sciences.

[4]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[5]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[6]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[7]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[8]  Sidra Nawaz,et al.  Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer , 2015, Modern Pathology.

[9]  James C. Whisstock,et al.  Perforin and granzymes: function, dysfunction and human pathology , 2015, Nature Reviews Immunology.

[10]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[11]  N. Restifo,et al.  The interplay of effector and regulatory T cells in cancer. , 2015, Current opinion in immunology.

[12]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[13]  U. Mahmood,et al.  Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization. , 2013, Cancer research.

[14]  G. Freeman,et al.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.

[15]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[16]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[17]  A. fong,et al.  Utilization rates, complications and costs of percutaneous liver biopsy: a population‐based study including 4275 biopsies , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[18]  N. Thornberry,et al.  Mouse and Human Granzyme B Have Distinct Tetrapeptide Specificities and Abilities to Recruit the Bid Pathway* , 2007, Journal of Biological Chemistry.

[19]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[20]  A. Berstad,et al.  Accuracy and complications in computed tomography fluoroscopy-guided needle biopsies of lung masses , 2006, European Radiology.

[21]  L. Gesualdo,et al.  Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. , 2004, Kidney international.

[22]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[23]  N. Thornberry,et al.  Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. , 2002, Bioorganic & medicinal chemistry letters.

[24]  H G Bull,et al.  The three-dimensional structure of human granzyme B compared to caspase-3, key mediators of cell death with cleavage specificity for aspartic acid in P1. , 2001, Chemistry & biology.

[25]  N. Thornberry,et al.  A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B , 1997, The Journal of Biological Chemistry.

[26]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[27]  E. Podack.  Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. , 1995, Current opinion in immunology.

[28]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  T. Torigoe,et al.  Immune-related adverse events of immune checkpoint inhibitors. , 2017, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[30]  A. Ribas,et al.  An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. , 2016, Cancer research.

[31]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  A. Dimitrakopoulou-Strauss,et al.  Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  M S Doscher,et al.  Solid-phase peptide synthesis. , 1977, Methods in enzymology.